SCREENING DIAGNOSTICS OF FABRIC DISEASE AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE IN THE NORTH-WESTERN REGION OF RUSSIA

Fabry disease (FD) is a progressive multi-organ disease leading to the development of cardiovascular and cerebrovascular complications and progression of renal failure. Nonspecificity of clinical signs often leads to late diagnosis of the FD that causes high diagnostic relevance of screening in high risk groups, particularly among patients with chronic kidney disease (CKD). According to the results of screening programs in many countries, the average prevalence of FD among patients with CKD is about 0.26%. THE AIM of this study was to investigate the prevalence of FD in patients with CKD in the northern west region of Russian Federation. PATIENTS AND METHODS. This prospective study assessed α-galactosidase A (α-Gal A) activity in dried blood spots in 1835 stage 1-5 CKD (85% – dialysis, 15% – pre-dialysis) patients, 74% males, mean age 55±12 years. The survey was carried out regardless of gender, age and primary diagnosis leading to CKD. The activity of α-Gal A more than 1.89 umol/l/hr was considered as normal. In the case of identifying the decreased activity of the enzyme the diagnosis was confirmed by GLA gene mutation analysis. RESULTS. The average level of α-Gal A was 5.39±2.69 umol/l/h. The level of α-Gal A was significantly higher in patients with pre-dialysis stages of CKD compared with patients receiving dialysis (7.5±3 vs 4.3±2.3 umol/l/h, p<0.001) as well as in males higher than in females (5.9±3.4 vs 3.4±2.3 umol/l/h, p <0.001). The decrease in α-Gal A activity was detected in 6 patients, of which 3 had the GLA gene mutations (c.427G>A, с.818Т>С, c.895G>C). One patient (p.508G> T) had a confirmed FD and received an enzyme-replacement therapy at the time of screening. All patients with identified FD were males treated by hemodialysis. Thus, the prevalence of FD in patients with CKD C5d was 1:392 (0.26%). A survey of relatives revealed the disease in two additional cases. CONCLUSION. The prevalence of Fabry disease in selected CKD patients of northern west region of Russian Federation is in the mean worldwide range. In all cases, the FD was not timely diagnosed, leading to serious organ damage and delaying the onset of enzyme replacement therapy. Thus, the screening of FD is necessary at the early stages of CKD.

1. Фомин ВВ, Пулин АА, Мухин НА. Нефропатия при болезни Фабри: возможности радикального улучшения прогноза при орфанных заболеваниях. Тер арх 2013; 6: 4–9 [Fomin VV, Pulin AA, Mukhin NA. Nefropatiya pri bolezni Fabri: vozmozhnosti radikal'nogo uluchsheniya prognoza pri orfannykh zabolevaniyakh. Ter arkh 2013; 6: 4–9]

2. Mehta A, Beck M, Eyskens F et al. Fabry disease: a review of current management strategies. QJM 2010; 103(9):641–659

3. Ramaswami U, Whybra C, Parini R et al. Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 2006; 95(1):86–92

4. Фомин ВВ, Пулин АА, Аксенова ОА и др. Тяжелое поражение подоцитов, выявленное при электронной микроскопии почечного биоптата, у пациента с болезнью Фабри без выраженных изменений мочи и почечной недостаточности. Клин нефрол 2012; 1: 55–58 [Fomin VV, Pulin AA, Aksenova OA i dr. Tyazheloye porazheniye podotsitov, vyyavlennoye pri elektronnoy mikroskopii pochechnogo bioptata, u patsiyenta s bolezn'yu Fabri bez vyrazhennykh izmeneniy mochi i pochechnoy nedostatochnosti. Klin nefrol 2012; 1: 55–58]

5. Schiffmann R, Hughes DA, Linthorst GE et al. Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017; 91(2):284– 293. Doi: 10.1016/j.kint.2016.10.004

6. Ortiz A, Cianciaruso B, Cizmarik M et al. End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant 2010; 25: 769–775

7. West M, Nicholls K, Mehta A et al. Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 2009; 20: 1132–1139

8. Terryn W, Cochat P, Froissart R et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 2013; 28(3):505–517

9. Eng CM, Fletcher J, Wilcox WR et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007;30:184–192

10. Barba-Romero MA, Rivera-Gallego A, Pintos-Morell G. Fabry disease in Spain: description of Spanish patients and a comparison with other European countries using data from the Fabry Outcome Survey (FOS). Int J Clin Pract 2011;65:903–910

11. Trachoo O, Jittorntam P, Pibalyart S et al. Screening of Fabry disease in patients with end-stage renal disease of unknown etiology: the first Thailand study. J Biomed Res 2016; 31(1):17–24 Doi: 10.7555/JBR.31.20160063

12. Моисеев СВ, Намазова-Баранова ЛС, Савостьянов КВ и др. Болезнь Фабри у пациентов, получающих лечение программным гемодиализом. Нефрология и диализ 2017; 3:382–388 [Moiseyev SV, Namazova-Baranova LS, Savost'yanov KV i dr. Bolezn' Fabri u patsiyentov, poluchayushchikh lecheniye programmnym gemodializom. Nefrologiya i dializ 2017;3:382–388] Doi: 10.28996/1680-4422-2017-3-382-388

13. Bono C, Nuzzo D, Albeggiani G et al. Genetic screening of Fabry patients with EcoTILLING and HRM technology. BMC Res Notes 2011; 4:323. Doi: 10.1186/1756-0500-4-323

14. Eng CM, Germain DP, Banikazemi M et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006; 8(9): 539–548

15. Niaudet P. Living donor kidney transplantation in patients with hereditary nephropathies. Nat Rev Nephrol 2010; 6(12): 736–743

16. Chamoles NA, Blanco M, Gaggioli D. Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. Clin Chim Acta 2001; 308(1-2): 195–196

17. Shi Q, Chen J, Pongmoragot J et al. Prevalence of Fabry disease in stroke patients – a systematic review and metaanalysis. J Stroke Cerebrovasc Dis 2014; 23(5): 985–992

18. Seo J, Kim M, Hong GR et al. Fabry disease in patients with hypertrophic cardiomyopathy: a practical approach to diagnosis. J Hum Genet 2016; 61(9): 775–780

19. Saip S, Uluduz D, Erkol G. Fabry disease mimicking multiple sclerosis. Clin Neurol Neurosurg 2007; 109(4): 361–363

20. Maruyama H, Miyata K, Mikame M et al. Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis. Genet Med 2018; 15. Doi: 10.1038/gim.2018.31. [Epub ahead of print]

21. Ouyang Y, Chen B, Pan X et al. Clinical significance of plasma globotriaosylsphingosine levels in Chinese patients with Fabry disease. Exp Ther Med 2018;15(4):3733–3742. Doi: 10.3892/etm.2018.5889. Epub 2018 Feb 26

22. Kotanko P, Kramar R, Devrnja D et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004; 15(5):1323–1329

23. Merta M, Reiterova J, Ledvinova J et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 2007;22(1):179–186

24. Kim JY, Hyun YY, Lee JE et al. Serum globotriaosylceramide assay as a screening test for fabry disease in patients with ESRD on maintenance dialysis in Korea. Korean J Intern Med 2010;25(4):415–421. Doi: 10.3904/kjim.2010.25.4.415.Ep

25. https://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/89407